TP1
Active fragment of thymopoietin that modulates T-cell differentiation and immune function.
3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Thymopoietin II Fragment (TP-1) is a compound studied only in animals and lab experiments so far. Active fragment of thymopoietin that modulates T-cell differentiation and immune function.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsNo published studies of a thymopoietin fragment named 'TP-1' found. The studied fragment is thymopentin (TP-5, residues 32-36); related fragments TP-3/TP-4 exist.Community-reportedCommunity-reported: Research varies, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a piece of a thymus hormone described as helping immune T cells mature, based on lab studies. Proposed mechanism, from in vitro and computational studies: thymopoietin and its active fragment thymopentin are described as inducing T-cell differentiation and regulating immune function (Onoue 2006); docking studies propose the T-cell receptor as a target (Kondratyev 2014).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, reported doses vary widely (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Thymopoietin II Fragment (TP-1) | Unknown | Subcutaneous injection | Preclinical (animal) |
| KPV | No published PK data found | Subcutaneous injection, Oral, Topical | Preclinical (animal) |
| LL-37 | Unknown | Subcutaneous injection | Phase 2 |
| Thymalin | No published PK data found | Intramuscular injection | Approved outside US |
| Thymosin Alpha-1 | No published human PK data found; ~3 h for native Tα1 in rats (Shen 2019). Literature describes a 'short plasma half-life' requiring twice-weekly s.c. dosing. | Subcutaneous injection | Approved outside US |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Immune category. View All Immune Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.